J Mal Vascul
-
Editorial Comment
[Aspirin for preventing the recurrence of venous thromboembolism].
-
Rivaroxaban is a direct oral anticoagulant targeting factor Xa. Efficacy and safety of rivaroxaban were evaluated through the phase 3 EINSTEIN program, consisting in three clinical trials regarding the treatment of deep vein thrombosis (EINSTEIN DVT), pulmonary embolism (EINSTEIN PE), and in secondary prevention after a first episode of venous thromboembolic disease (EISNTEIN EXT). Rivaroxaban was recently approved both by the European and the French Health agencies for the treatment of DVT and prevention of deep vein thrombosis recurrence. This report addresses the use of rivaroxaban in clinical practice in such indications.
-
To assess the most accurate clinical signs and clinical scoring for selecting patients who could benefit from duplex sonography screening of deep venous thrombosis (DVT) after total hip replacement (THR) and total knee replacement (TKR). ⋯ After THR or TKR, DCC> 3 cm or a clinical risk score greater or equal to 4 could be used as an accurate and easy clinical test for assessing the need for further DVT screening by sonography.